Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Robson

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 21, 2001
Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutationsN D Kauff, L Scheuer, M E Robson, et al.
Journal of Medical Genetics|August 6, 2002
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer familiesN D Kauff, P Perez-Segura, M E Robson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinomaJ L Grem, E Jordan, M E Robson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerM E Robson, N Tung, P Conte, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trialS A Hurvitz, R G W Quek, N C Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trialP S Schmid, H L McArthur, J Cortés, et al.
Journal of Medical Genetics|October 6, 2010
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancersK A Schrader, S Masciari, N Boyd, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 21, 2001
Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutationsN D Kauff, L Scheuer, M E Robson, et al.
Journal of Medical Genetics|August 6, 2002
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer familiesN D Kauff, P Perez-Segura, M E Robson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinomaJ L Grem, E Jordan, M E Robson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerM E Robson, N Tung, P Conte, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trialS A Hurvitz, R G W Quek, N C Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trialP S Schmid, H L McArthur, J Cortés, et al.
Journal of Medical Genetics|October 6, 2010
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancersK A Schrader, S Masciari, N Boyd, et al.
Pageof 2